Takeda Pharmaceutical Co Ltd ADR
$ 17.06
-2.79%
21 Apr - close price
- Market Cap 55,443,833,000 USD
- Current Price $ 17.06
- High / Low $ 17.29 / 17.06
- Stock P/E 79.77
- Book Value 15.23
- EPS 0.22
- Next Earning Report 2026-05-14
- Dividend Per Share $198.00
- Dividend Yield 3.77 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.02 %
- 52 Week High 18.90
- 52 Week Low 12.78
About
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Analyst Target Price
$20.53
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-29 | 2025-10-30 | 2025-07-30 | 2025-05-08 | 2025-01-30 | 2024-10-31 | 2024-07-31 | 2024-05-09 | 2024-02-01 | 2023-10-26 | 2023-07-27 | 2023-05-22 |
| Reported EPS | 0.2099 | -0.0253 | 151 | -0.2276 | 0.0478 | 29.07 | 0.1923 | -0.0065 | 33.79 | -15.5 | 28.76 | 0.074 |
| Estimated EPS | None | 0.151 | 0.2006 | -0.166 | 0.63 | 87.45 | 0.1228 | -0.0142 | 0.1085 | 0.1441 | 18.62 | 0.0505 |
| Surprise | 0 | -0.1763 | 150.7994 | -0.0616 | -0.5822 | -58.38 | 0.0695 | 0.0077 | 33.6815 | -15.6441 | 10.14 | 0.0235 |
| Surprise Percentage | None% | -116.755% | 75174.1775% | -37.1084% | -92.4127% | -66.7581% | 56.5961% | 54.2254% | 31042.8571% | -10856.4192% | 54.4576% | 46.5347% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.21 |
| Currency | JPY |
Previous Dividend Records
| Dec 2025 | Jul 2025 | Dec 2024 | Jul 2024 | Dec 2023 | Jul 2023 | Dec 2022 | Jul 2022 | Jul 2021 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-12-11 | 2025-07-07 | 2024-12-12 | 2024-07-08 | 2023-12-11 | 2023-07-10 | 2022-12-12 | 2022-07-11 | 2021-07-12 | None |
| Amount | $0.322144 | $0.33901 | $0.326079 | $0.292214 | $0.319068 | $0.30996 | $0.329553 | $0.330062 | $0.406627 | $0.4191 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TAK
2026-04-21 10:39:01
Takeda Pharmaceutical (TSE:4502) has seen significant share gains over multi-year periods but has recently experienced a slight decline. A discounted cash flow (DCF) analysis suggests the stock is undervalued by 71.0% compared to its intrinsic value. However, its current P/E ratio of 76.87x is significantly higher than the industry average, indicating the shares screen as overvalued based on earnings.
2026-04-21 07:39:01
Takeda Pharmaceutical is focusing on rare diseases and plasma-derived therapies to drive growth and maintain revenue stability. This strategy aims to leverage high-margin specialized drugs, providing a less volatile investment opportunity compared to traditional U.S. Big Pharma. The company's acquisition of Shire and its global footprint strengthen its competitive position against patent cliffs and generic pressures.
2026-04-20 21:10:26
TAKEDA PHARMACEUTICALS AMERICA INC disclosed $1,410,000 in lobbying expenditures for Q1 2026, covering issues like patient access to medicines, Medicare policies, and the Inflation Reduction Act. The report also highlights recent hedge fund activity in TAK stock, with several institutions increasing or decreasing their positions. This financial and lobbying data is provided by Quiver Quantitative.
2026-04-20 19:10:26
Takeda Pharmaceutical is focusing on rare diseases and plasma therapies to drive steady growth and mitigate patent cliffs. The company's strategy emphasizes high-margin, specialized drugs and long-term R&D in areas with unmet needs, supported by global market ties. While facing risks like patent expirations and execution hurdles, Takeda's competitive position and pipeline depth make it an interesting play for investors seeking exposure to high-margin biotech without the volatility of U.S. Big Pharma.
2026-04-20 03:09:47
Takeda Pharmaceutical Company Limited, with a 245-year legacy, is committed to patient-first innovation in Malaysia's evolving healthcare landscape. The company focuses on addressing chronic, complex, and critical diseases, supporting the healthcare ecosystem, and strengthening patient care through partnerships and scientific advancements. Takeda plans to launch up to nine new products in Malaysia over the next five years, emphasizing oncology, inflammation, and neuroscience, while upholding its founding principle of treating patients as if they were one's own children.
2026-04-18 11:10:10
Takeda Pharmaceutical (TSE:4502) has experienced a recent 4.8% share price decline over the past month, despite a 10.1% gain over three months and a 35.6% total shareholder return over one year. The company is currently trading at ¥5,586, with its most followed valuation narrative suggesting a fair value of ¥6,003, implying it is 7% undervalued due to its late-stage pipeline and easing patent pressures. However, its high P/E ratio of 78.1x, compared to the industry average of 15.5x, signals potential valuation risks from earnings expectations.
